Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025258 | PMC |
| http://dx.doi.org/10.1038/s41392-023-01322-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China.
Front Pharmacol
November 2024
Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China.
[This corrects the article DOI: 10.3389/fphar.2024.
View Article and Find Full Text PDFPyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.
EClinicalMedicine
October 2024
Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
Background: The phase 2 PERMEATE study has shown the antitumor activity and safety of pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases. In this report, survival results were updated with extended follow-up.
Methods: Between January 29, 2019 and July 10, 2020, adult patients with HER2-positive metastatic breast cancer who had radiotherapy-naïve brain metastases (cohort A, n = 59) or progressive disease after radiotherapy (cohort B, n = 19) were enrolled and received pyrotinib (400 mg once daily) and capecitabine (1000 mg/m twice daily on days 1-14 of each 21-day cycle) until disease progression or unacceptable toxicity.
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study.
Ther Adv Med Oncol
September 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Background: Inetetamab is a novel antibody targeting human epidermal growth factor receptor 2 (HER2) developed in China. Due to its optimized antibody-dependent cell-mediated cytotoxicity effect compared with trastuzumab, it has shown good efficacy and safety in the treatment of HER2-positive advanced breast cancer (ABC).
Objectives: This study aimed to investigate the efficacy and safety of inetetamab combination therapy in the treatment of HER2-positive ABC in real-world clinical practice.
Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases.
Front Pharmacol
August 2024
Department of Head and Neck Oncology, Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China.
Brain metastases (BM) represent a common and severe complication of breast cancer (BC), emerging in approximately 10%-16% of all BC patients. The prevalent approach for treating BC patients with BM encompasses a multimodal strategy, combining surgery, whole brain radiation therapy, and stereotactic radiosurgery. Yet, a concrete guideline for localized treatment strategies remains elusive, while systemic treatments like small-molecule-targeted therapy and immunotherapy are still in the clinical trial phase.
View Article and Find Full Text PDFCombination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer After Trastuzumab Failure (PROVE): A Prospective Phase 2 Study.
Cancer Res Treat
August 2024
Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Article Synopsis
- A study evaluated the effectiveness and safety of pyrotinib combined with metronomic vinorelbine for patients with HER2-positive advanced breast cancer who did not respond to trastuzumab treatment.
- The trial involved 36 patients and reported a median progression-free survival (PFS) of 13.5 months, with an overall response rate (ORR) of 38.9% and a disease control rate (DCR) of 83.3%.
- Common side effects included diarrhea and vomiting, but no severe adverse events were noted, indicating a promising treatment option for these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!